Patents by Inventor Richard G. Pestell

Richard G. Pestell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170231991
    Abstract: This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: August 17, 2017
    Inventor: Richard G. Pestell
  • Patent number: 9453836
    Abstract: This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: September 27, 2016
    Inventor: Richard G. Pestell
  • Publication number: 20160139132
    Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.
    Type: Application
    Filed: December 10, 2015
    Publication date: May 19, 2016
    Applicant: Thomas Jefferson University
    Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
  • Publication number: 20140221496
    Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.
    Type: Application
    Filed: November 26, 2013
    Publication date: August 7, 2014
    Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
  • Publication number: 20140109245
    Abstract: The present disclosure, in part, is directed to a mammalian prostate cancer cell line comprising at least one or a set of primary mammalian epithelial cells which have been infected with a retroviral vector carrying an oncogene selected from the group consisting of c-Myc, Ha-Ras, NeuT, c-Src and combinations thereof and in which said gene is expressed.
    Type: Application
    Filed: March 9, 2012
    Publication date: April 17, 2014
    Inventor: Richard G. Pestell
  • Publication number: 20130303512
    Abstract: This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
    Type: Application
    Filed: May 14, 2013
    Publication date: November 14, 2013
    Inventor: Richard G. PESTELL
  • Publication number: 20130011411
    Abstract: Methods and compositions for diagnosing and treating cancer, such as breast cancer are provided. In particular, methods and compositions relating to nucleic acids encoding DACH1 and DACH1 proteins are provided.
    Type: Application
    Filed: January 6, 2011
    Publication date: January 10, 2013
    Inventors: Richard G. Pestell, Kongming Wu, Xuanmao Jiao, Sanjay Katiyar, Vladimir M. Popov, Mathew Casimiro
  • Publication number: 20120190565
    Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.
    Type: Application
    Filed: February 18, 2010
    Publication date: July 26, 2012
    Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
  • Publication number: 20120039805
    Abstract: The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial; lymphomas, sarcomas, melanomas, and the like, comprising determining the level of caveolin-1 and/or caveolin-2 in stromal cells adjacent to a neoplasm.
    Type: Application
    Filed: February 19, 2010
    Publication date: February 16, 2012
    Inventors: Michael P. Lisanti, Federica Sotgia, Richard G. Pestell
  • Patent number: 8076318
    Abstract: Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene of interest operably linked to a genetic element capable of being induced by the receptor when bound to a ligand, and the receptor not naturally present in the species of the cell. The cells also comprise a caged ligand of the receptor. Additionally provided are methods of inducing a gene of interest in the above cells. Also provided are methods of repressing a gene of interest in a cell using caged ligands of receptors. Methods are additionally provided for inducing elimination of a target sequence in a cell of a species, using a caged ligand and a recombinase.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: December 13, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David S. Lawrence, Richard G. Pestell, Christopher Albanese